At this year’s San Antonio Breast Cancer Symposium, new data results from four different clinical trials of bisphosphonate usage in patients with breast cancer will be presented and discussed.
The San Antonio Breast Cancer Symposium brings together basic science researchers and clinicians for the latest breast cancer research-related progress. The symposium has evolved from a 1-day local conference to a 5-day international meeting focusing on clinical, preventive, diagnostic, translational, and basic research.
Is estrogen plus progestin better than estrogen alone for symptom relief in menopausal women? For women who have not had a hysterectomy, adding progestin to estrogen therapy counteracts the increased risk of uterine cancer from estrogen monotherapy. However, the progestin and estrogen combination increases breast cancer risk. The combination treatment also comes with its own side effects, including breast tenderness, which ranges from 8% to 15% of patients in randomized clinical trials.
Coffee is emerging as a protective agent against a number of diseases, including cancer. A study published last week shows that women who drank more than four cups of coffee per day cut their risk of endometrial cancer by 25% compared with those who drank less than one cup per day.
Immunotherapy is finally getting the cancer clinical and research community excited: A large portion of the presentation and discussion at the Melanoma International Congress, held in Tampa, Florida last week focused on immunotherapy approaches for the treatment of the disease.
The US Food and Drug Administration announced today that it has revoked the approval of bevacizumab for breast cancer due to the potentially life-threatening side effects associated with the treatment. It was approved for metastatic breast cancer in February 2008, but data later showed that along with an increase in side effects, there was no increase in overall survival.
The theme of the SMR meeting in Tampa this year was “Advancement through Collaboration," and this theme was clearly reflected in the meeting.
With positive read-outs from trials over the last two years and approval of two new agents for the disease, Yervoy and Zelboraf, the field is already looking to new agents and combination trials to improve patient outcomes and survival.
The results of a trial comparing concurrent versus sequential trastuzumab and chemotherapy as adjuvant treatment of breast cancer has shown an improved efficacy without increased toxicity for the concurrent regimen.
Breast and ovarian cancer patients with limited tumor burden and minimal prior chemotherapy appear to have benefited from a novel vaccine.